Novo Nordisk Gets CDSCO Panel Nod To study CDR132L Dr. Divya Colin23 Feb 2025 6:00 PM ISTNew Delhi: Novo Nordisk has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
Lupin's Generic Entresto Approved by USFDA, Set to Rival Novartis' Bestseller Farhat Nasim29 Jan 2025 8:04 PM ISTMumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received approval from the U.S....
Entresto: Novartis loses initial bid to block generic of blockbuster heart drug Ruchika Sharma14 Aug 2024 11:30 AM ISTLondon: Novartis, a leading pharmaceutical company, has failed in its attempt to convince a federal court to block MSN Pharmaceuticals, a generic...
Novartis Gets CDSCO Panel Nod to Study XXB750 in Patients With Heart Failure Dr. Divya Colin2 Feb 2024 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Semaglutide effective in improving symptoms in obese heart failure patients, NEJM study dr. Abhimanyu Uppal28 Sept 2023 10:45 AM ISTSemaglutide, a glucagon-like peptide 1 (GLP-1) agonist is the latest entry in the arena of medications combating heart failure with preserved ejection...
Novartis sues US government over Medicare drug price regulation Ruchika Sharma4 Sept 2023 11:31 AM ISTThe pharmaceutical industry says the program will curtail profits and compel it to pull back on developing new treatments.
Interim relief to Novartis: Delhi HC reinstates Entresto (Sacubitril-Valsartan) patent in India Farhat Nasim27 Jan 2023 6:26 PM ISTDelhi: In an interim relief to Swiss pharma major Novartis, the Delhi High Court has reinstated Entresto (sacubitril/valsartan) patent in India amid...
Novartis in tight spot as HC stays grant of patent for Entresto amid generics fight Farhat Nasim13 Jan 2023 11:59 AM ISTNew Delhi: Amid the earlier patent of blockbuster heart failure drug Entresto expiring on January 16, 2023 concerns rise for the Swiss multinational...
Critical Heart Failure drug gets Cheaper, JB Pharma cuts prices of Azmarda by 50 percent Dr. Nandita Mohan8 Dec 2022 1:03 PM ISTMumbai: Treatment of Heart Failure will get more affordable in India, as makers of the heart failure drug Azmarda, JB pharma, has announced a...
JB Pharma slashes price of critical Heart Failure medicine AZMARDA (Sacubitril-Valsartan) by nearly 50 percent Ruchika Sharma5 Dec 2022 2:37 PM IST"This move by JB will not only help reduce the cost of treatment but will also help enhance the productive years of patients and their quality of...
Long acting Ivabradine improves cardiac function in heart failure patients: FIRST study dr. Abhimanyu Uppal3 Aug 2022 10:00 AM ISTAlthough Ivabradine has been shown to improve clinical outcomes of chronic heart failure but the conventional formulation has the disadvantage of...
JBCPL gets trademark assignment of heart failure drug Azmarda from Novartis Roshni Dhar5 April 2022 5:45 PM ISTJB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for...
